Skip to content

RESPOND: Improving mental healthcare for labour migrants in the Netherlands during the COVID-19 pandemic

Implementation of a stepped care program (DWM/PM+)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON27052
Enrollment
212
Registered
2021-07-20
Start date
2021-09-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common mental disorders

Interventions

The study has two arms: 1. Control group: participants receive care-as-usual (CAU) and Psychological First Aid (PFA). 2. Treatment group: participants receive care-as-usual (CAU), Psychological First
it does not completely cover mental health service costs. Labour migrants who signed up for the basic health insurance package (which is obligated for everyone who plans to stay for more than 4 months

Sponsors

Vrije Universiteit Amsterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - 18 years or older - Living in the Netherlands as labour migrant - Having elevated levels of psychological distress (Kessler Psychological Distress Scale (K10) >15.9). - Sufficient mastery (written and spoken) of one of the languages the DWM/PM+ intervention is being delivered in (e.g. Polish, English).

Exclusion criteria

Exclusion criteria: - Planning to permanently move back to their home country before the last quantitative assessment at 2 months after PM+ - Having acute medical conditions (requiring hospitalisation) - Imminent suicide risk, or expressed acute needs or protection risks that require immediate follow-up - Having a severe mental disorder (e.g. psychotic disorders, substance-dependence) - Having severe cognitive impairment (e.g. severe intellectual disability or dementia) - Currently receiving specialised psychological treatment (e.g. EMDR, CBT) - In case of current psychotropic medication use: being on an unstable dose for at least 2 months or a change in dosage over the past 2 months.

Design outcomes

Primary

MeasureTime frame
The primary outcome will be the decrease in symptoms of anxiety and depression from baseline to two-month follow-up, measured through the sum score of the Patient Health Questionnaire (PHQ-9) and General Anxiety Disorder-7 (GAD-7), i.e. the PHQ-Anxiety and Depression Score (PHQ-ADS).

Secondary

MeasureTime frame
Secondary outcomes will be reported separately, according to different prespecified research questions and planned analyses. Clinical secondary outcomes are depressive symptoms (PHQ-9), anxiety symptoms (GAD-7), and posttraumatic stress symptoms (PCL-5). Resilience-related outcomes/measures include stressor exposure assessed with the Mainz Inventory of Microstressors (MIMIS) and positive appraisal style assessed with the Positive Appraisal Style Scale, content-focused (PASS-content). Cost-effectiveness outcomes include quality of life (EQ-5D-5L) and care/resource use (CSRI).

Contacts

Public ContactRinske Roos

Vrije Universiteit Amsterdam

r.roos@vu.nl+31 20 598 58 48

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 11, 2026